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The gene of caspase-activated DNase (CAD), the key enzyme for nucleosome cleavage during apoptosis, is mapped at chromosome
1p36, a region usually associated with hemizygous deletions in human cancers, particularly in hepatoma (HCC). It is tempting to
speculate that CAD plays a tumour-suppressive role in hepatocarcinogenesis. To address this, we examined the CAD transcripts in
six human HCC cell lines, one liver tissue from a non-HCC subject, and peripheral blood leukocytes (PBL) from three healthy
individuals. Alternatively spliced CAD transcripts with fusion of exon 1 to exon 7 were isolated in most of the examined samples
including HCC cells and normal controls. However, relatively abundant alternatively spliced CAD transcripts with fusion of exon 2 to
exon 6 or 7, in which the corresponding domain directing CAD interaction with ICAD was preserved, were found only in poorly
differentiated Mahlavu and SK-Hep1 cells. Interestingly, an abnormal CAD transcript with its exon 3 replaced by a truncated
transposable Alu repeat was isolated in Hep3B cells, indicative of the implication of an Alu-mediated genomic mutation. Moreover,
mis-sense mutations in the CAD genes were identified in all six HCC cell lines. Upon UV-induced apoptosis, DNA fragmentation
efficiency was found to be intact, partially reduced and remarkably reduced in Huh7 and J328, Hep3B and HepG2, and Mahlavu cells,
respectively. That mutations and aberrantly spliced transcripts for the CAD gene are frequently present in human HCC cells, especially
in poorly differentiated HCC cells, suggests a significant role of CAD in human hepatocarcinogenesis.
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Apoptosis is a programmed cell death process that removes toxic
or useless cells during mammalian development (Wyllie, 1980).
The biological hallmark of apoptosis is the cleavage of chromo-
somal DNA into nucleosomal fragments (Wyllie, 1980). Human
caspase-activated DNase (CAD, also called DFF40/CPAN) is the
key enzyme for nucleosome cleavage during cell apoptosis (Liu
et al, 1997; Enari et al., 1998; Halenbeck et al, 1998; Mukae et al,
1998). CAD contains two different functional domains: the N-
terminal regulatory domain (CIDE-N or CAD domain) and the C-
terminal catalytic domain. The CAD domain shares sequence
homology with the N-terminal of the inhibitor of CAD (ICAD) (Liu
et al, 1997; Mukae et al., 1998). Structural and mutational analyses
of the CAD domains revealed that they account for the ability of
CAD and ICAD to form a heterodimer (Inohara et al, 1999;
Lugovskoy et al, 1999; Uegaki et al, 2000; Zhou et al, 2001). ICAD
inhibits CAD activity by binding to CAD. During the apoptotic
process, CAD is released from the ICAD/CAD complex via
proteocleavage of the ICAD by caspase 3 or caspase 7. CAD then
degrades chromosomal DNA. Moreover, ICAD also works as a
chaperon to help the correct folding of the CAD protein (Enari
et al, 1998; Zhang et al, 1998; Sakahira et al., 1999). The active CAD
can be synthesised only in the presence of ICAD both in vitro and
in vivo. The CAD synthesised in vitro without ICAD does not have
DNase activity at all.
Inactivation of CAD has been shown to render cells resistant to
undergoing apoptosis (Sakahira et al, 1998) and may cause cell
transformation. Recently, human CAD gene was mapped at
chromosome 1p36.3 (Mukae et al, 1998). Human chromosome
1p36 is frequently associated with hemizygous deletions in several
types of cancers, particularly in hepatocellular carcinoma (HCC),
indicating the presence of one or more tumour suppressor genes in
the region (Buetow et al, 1989; Simon et al, 1991; Yeh et al, 1994).
It is, therefore, tempting to speculate that CAD might be one of the
tumour suppressors for hepatocellular carcinogenesis. To address
this hypothesis, we examined the CAD transcripts in human HCC
cells.
MATERIALS AND METHODS
Hepatoma cell lines, liver tissue and peripheral leukocytes
Human hepatoma cell lines, HepG2, Hep3B, Huh7, Sk-Hep1 (Fogh
et al, 1977; Chang et al, 1993), and Mahlavu were obtained from
American Type Culture Collection (Manassas, VA, USA), while
J328 was kindly provided by Dr CS Yang (Chen et al, 1994). All
media were supplemented with 10% (v/v) foetal bovine serum and
2m ML -glutamine. One non-HCC liver sample, obtained from a
patient who received liver resection on account of a benign focal
nodular hyperplasia of the liver, and peripheral blood leukocyte
(PBL) samples obtained from three healthy individuals were
included in the study as non-HCC controls. The liver sample was
frozen immediately in liquid nitrogen after resection and stored at
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y 801C until processing. The Ethics and Science Committee of
Chang Gung Memorial Hospital approved specimen collection
procedures and informed consent was obtained from each subject
or subject’s guardian.
RNA preparation and RT–PCR
Total cellular RNA was extracted from HCC cell lines, liver tissue
and peripheral blood leukocytes using the single-step acid–phenol
extraction method as described before (Lin et al, 2001). Total RNA
(2mg) was converted to cDNA via a random-primer method as
described previously (Hsieh et al, 1997). The whole reading-frame
of the CAD gene was cloned using nested PCR (Figure 1A). In
brief, 1/50th of the cDNA was subjected to amplification for the
first round of PCR in a total volume of 50ml, which contained
4pmol of each primer, 200nM of each dNTP, and 2U of Taq DNA
polymerase in a buffer containing 40mM Tricine-KOH (pH 8.7),
3.5mM MgCl2,1 5 m M KOAc, 0.005% Tween-20 and 0.005%
Nonidet-P40 (Advantage 2 PCR kit, CLONTECH, Palo Alto, CA,
USA). Amplification was performed using 30 cycles of 951C for
30s, 651C for 4min. The first-round PCR products were diluted
1/50 and 1ml of the dilute was subjected to the second round
of PCR with the inner primer pairs using conditions similar to that
of the first-round PCR. After gel-electrophoresis analysis, the
second-round PCR products were directly cloned using a
PCR-TA cloning kit (pCRII TOPO, Invitrogen, Carlsbad, CA,
USA). At least 10 clones derived from each HCC cell line and
the liver sample, and at least five clones from each peripheral
blood leukocyte samples were randomly selected for sequencing
analysis. Sequencing analysis, using the two primers encoded
in the vector and the two CAD-specific primers as illustrated
in Figure 1a, was conducted as described before (Hsieh et al,
1999).
The primer sequences for the nested PCR were as follows:
First-round PCR: 50-CCCAGAGGGCTTGAGGACATCTGCAA-30
50-ACCAGGACGTGGTGTGTACGTGTCA-30
Second-round PCR: 50-GAGGACATCTGCAATGCTCCAGAAGC-30
50-TCACTGGCGTTTCCGCACAGGCTG-30
The sequences of the primers for sequencing are:
T7 primer: 50-GTAATACGACTCGCTATAGGG-30
SP6 primer: 50-TATTTAGGTGACACTATAG-30
CAD sense: 50-GTGGTTTGAACGCTTGCAGTCCCCGA-30
CAD antisense: 50-GACCGGAGCCTCTGGCACGTGGA-30
The nucleotide numbering used in this report is according to the
numbering system by Mukae et al (1998) (GenBank accession
numer: AB013918).
UV irradiation and DNA fragmentation
At 24h after plating (2 10
6/100mmdish), cells were irradiated
with 50–200mJcm
 2 of UV and harvested for DNA fragmentation
at 60, 90, 120, 150, 180 and 210min thereafter, respectively. PBS-
washed cells were suspended in DNA extraction buffer containing
50mM Tris (pH 8.0), 10mM EDTA, 0.5% N-laurosarcosine and
1mgml
 1 proteinase K, and incubated for 1h at 501C in a water
bath. Then DNase-free RNase was added at a final concentration of
250mgml
 1,a t5 0 1C for another hour followed by ethanol
precipitation of DNA. The DNA pellets were resuspended in TE
buffer (10mM Tris, pH 8.0/1mM EDTA). DNA (1mg) was end
labelled with a
32P-dATP in a solution containing 1mg DNA, 0.5
mCi a
32P-dATP, 5U Klenow polymerase, 10mM Tris, pH 7.5, 5mM
MgCl2 for 30min at room temperature. The reaction was
terminated by adding an equal volume of 10mM EDTA. The
labelled DNA was purified via a Sephadex G-50 spin-column
(Pharmacia Biotech, Quarry Bay, Hong Kong), and analysed by
electrophoresis on a 1% agarose gel and then by autoradiography.
For quantification of DNA fragmentation upon UV-induced
apoptosis in each HCC cell line, we used a cellular DNA
fragmentation ELISA kit in accordance with the manufacturer’s
instruction (Roche Diagnostics GmbH, Mannheim, Germany). In
brief, cells were metabolically labelled with 10mM of thymidine
analogue BrdU for overnight. At 4h after UV irradiation with 0,
100 or 200mJcm
 2, cell membrane was lysed for 30min at 201Ci n
a solution containing 10mM EDTA and 0.1% Tween-20. Following
centrifugation for 10min at 2500g to remove cellular debris and
nucleus component, the cytoplasmic lysate was subjected to an
ELISA to detect fragmented DNA in cytoplasm.
RESULTS
To study abnormalities in the CAD transcripts in HCC, we reverse
transcribed mRNA and amplified the complete CAD coding
sequences by nested PCR (Figure 1). As illustrated in Figure 2,
the 1-kb PCR products, which represented the full-length CAD
transcripts, were detected in all the examined samples. Small PCR
products, about 0.34kb, representing sub-full-length CAD tran-
scripts were found in the non-HCC liver sample and in PBL from
the three normal individuals (Figure 2B), whereas 0.45-kb and
0.55-kb PCR products for sub-full-length CAD transcripts were
detected in Mahlavu and SK-Hep1 cells, respectively (Figure 2A,
lanes 5 and 6). The PCR products were directly cloned. At least 10
clones derived from each hepatoma cell line and non-HCC liver
sample and at least five clones derived from each PBL sample
were randomly selected for sequencing analysis. The sequencing
results have been deposited in the GenBank and are summarised in
Table 1.
The prototype transcripts were found in HepG2, Huh7 cells,
non-HCC liver sample and the three PBL samples (Table 1). The
full-length transcripts with single-nucleotide polymorphism (SNP)
without change of amino acid were identified in J328 cells (wild
type, in terms of amino-acid sequences). In addition, the full-
length transcripts with SNP leading to amino-acid changes (mis-
sense mutations) were noted in all of the 6 HCC cell lines (Table 1).
All these mis-sense mutations corresponding to the CAD reading-
frame are illustrated in Figure 3. No hotspot for these mis-sense
mutations in CAD was found, although most of them were located
in the catalytic domain of CAD.
Sub-full-length transcripts were found in all of the six hepatoma
cell lines (Figure 4A), even though sub-full-length transcripts were
detected by gel electrophoresis only in Mahlavu and SK-Hep1
among the six examined HCC cell lines. In HepG2 cells, a minor
sub-full-length transcript (one out of the 10 selected clones) with a
deletion from nt 367 to nt 702 was identified. Of note, a four-
nucleotide identity, CTGC, was noted exactly at both of the 50- and
30-deletion ends (nucleotides 367–370 and 703–706), suggesting
Exon 1  Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7
nt 1 1017
cloning
sequencing
Figure 1 Schematic representation of the strategies for cloning and
sequencing of the CAD cDNA. The CAD reading frame was cloned using
nested RT–PCR method with two rounds of PCR following reverse
transcription. Two primer pairs for amplification of the nested PCR are
shown (arrows in both ends of the CAD reading frame). After examination
with gel electrophoresis, the PCR products were cloned directly and then
subjected to sequencing analysis using two vector primers (stippled arrows)
flanking the cloning site and two CAD-specific primers (stippled arrows
inside the reading frame).
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aberrant CAD transcript (three out of the 10 clones) corresponded
to replacement of exon 3 with a 121-base sequence, which was
homologous to part of the human transposon, Alu repeat. In both
Huh7 and J328 cells, there were minor small transcripts (two and
one out of the 10 clones, respectively) with the absence of exons 2–
6 resulting in conjunction of exon 1 to exon 7, suggestive of
transcripts derived from an alternative splicing process. Similar
alternatively spliced CAD transcripts with fusion of exon 1 to exon
7 were also noted in the non-HCC liver tissue and the three PBL
samples as well (Figure 2B and Table 1). In Mahlavu and SK-Hep1
cells, relatively abundant alternatively spliced transcripts (three
and seven out of the 10 clones, respectively) coincided with the
absence of exons 3 to 6, or to 5 leading to fusion of exon 2 to exon
7 or 6, respectively (Table 1 and Figure 4A).
The predicted amino-acid sequences for these aberrant tran-
scripts are aligned to that of the prototype CAD and shown in
Figure 4B. Of note, the amino-acid sequences for CAD domain (aa
1–80) were preserved in the aberrant CAD transcripts identified in
HepG2, Hep3B, Mahlavu and SK-Hep1 cells.
To inspect the nucleosome cleavage activity of CAD during
apoptosis in these HCC cell lines, DNA fragmentation assay was
conducted after UV induction of apoptosis. As shown in Figure 5,
the relative efficiency of DNA fragmentation upon UV irradiation
in HepG2, Hep3B, Huh7, J328 and Mahlavu cells was 0.56-, 1.26-,
1.60-, 1.81- and 0.87-fold, respectively, as compared to that in
M12345678
M12345
bp
1000
500
bp
1000
500
A
B
Figure 2 Expression of the CAD gene by nested RT-PCR. After reverse
transcription, the samples derived from six HCC cell lines were subjected
to two rounds of PCR as described in the legend of Figure 1. (A) Lanes 1–
8 represent the size marker, the PCR products derived from HepG2,
Hep3B, Huh7, J328, Mahlavu, SK-Hep1 cells and the non-HCC liver sample,
respectively. Of note, HepG2 and Hep3B are well-differentiated HCC cells,
Huh7 and J328 are moderately differentiated HCC cells, and Mahlavu and
SK-Hep1 are poorly differentiated HCC cells. (B) Lanes 1–5 represent the
PCR products derived from the non-HCC liver sample and from the three
PBL samples and a negative control for PCR respectively.
Table 1 Variants of CAD cDNA in human HCC cell lines, non-HCC liver tissue and PBL
The CAD cDNA clones
Cell line Exon 1 2 3 4 5 6 7
HepG2 ’ ’’’’’’Prototype
* ’’’* ’’G33S/S225
’’ || ’ n367–702
Hep3B ’’ ’ ’ * ’’R196K
’’ A ’’’’Alu repeat replacement
Huh7 ’ ’’’’’’Prototype
’ * ’’’’’L89P
’ ’ Exons 1–7
J328 ’ ’’’’’’SNP ACG177ACA
’’ **’’’E110Q/Q150R
’ ’ Exons 1–7
Mahlavu ’’ ’ ’ * ’’V171A
’’ ’ Exons 1–2–7
SK-Hep1 ’’ ’ ’ * ’ * E184L/K264T
’’ ’ ’ Exons 1–6–7
Non-HCC liver ’ ’’’’’’Prototype
’ ’ Exons 1–7
PBL ’ ’’’’’’Prototype
’ ’ ’’’’Skipping exon 3
’ ’ Exons 1–3
PBL ’ ’’’’’’Prototype
’ ’ ’’’’Skipping exon 3
’ ’ Exons 1–7
PBL ’ ’’’’’’Prototype
’ ’ Exons 1–7
*: mis-sense mutation; A: the Alu repeat; n: deletion with CTGC repeats at both ends; 1: incomplete exon sequences.
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UV irradiation in HepG2 cells was attributable to a relatively low
susceptibility to UV-induced apoptosis (data not shown).
DISCUSSION
Herein we report the identity of aberrant CAD transcripts in
human HCC cells. Two classes of human CAD cDNA have been
cloned by Mukae et al (1998). One encompasses the entire coding
region, whereas the other contains many deletions, insertions and
point mutations in the corresponding coding region. The latter is
thought to be derived from a pseudogene (Mukae et al, 1998).
Obviously, the subfull-length CAD cDNAs reported herein were
not derived from pseudogenes. Instead, most of them were more
likely generated via aberrant RNA processing mechanisms.
The minor CAD transcript (representing one out of the 10
isolated CAD cDNA clones) in HepG2 cells with a deletion from
nucleotides 367 to 702 possibly resulted from a recombination
processing, because of a four-nucleotide identity, CTGC, noted
exactly in both the deletion ends (nucleotides 367–370 and 702–
705, respectively). Two different species of full-length CAD
transcripts, a prototype and a transcript with mis-sense mutations,
were identified, suggesting that the recombination occurs more
amino acid 1                     80
CAD domain                 Catalytic domain
G33S          L89P E110G     V171A R196K S225P K264T
Q150R  E184K       
338
Figure 3 Scheme of mapping the mis-sense mutations to the corres-
ponding CAD reading frame. Amino acids 1–80 is the CIDE-N or CAD
domain that directs interaction with ICAD; the C-terminal is the catalytic
domain containing nuclease activity.
Prototype
HepG2 
Hep3B
Huh 7 
J328 
Mahlavu 
Sk-Hep 1 
nt 1 
Aberrants/Total CAD 
 cDNA (%) 
10 
30 
20 
10 
30 
70 
nt 1  366  703 
nt 1  241  431 
nt 1  783 
nt 1  241  783 
nt 1  241  708 
1 2 3 4  5  6 7
7 1 2 
1 
1 2 
1 2  6 
1 2 2  4  5 6  Alu
nt 1 
114
783 
1 
7
7
7
7
7
1017
1017
1017
1017
1017
1017
1017
A
B  12 1  4 1   6 1
Proto-type  MLQKP KSVKL RALRS PRKFG VAGRS CQEVL RKGCL RFQLP ERGSR LCLYE DGTEL TEDYF PSVPD NAELV 
HepG2 MLQKP KSVKL RALRS PRKFG VAGRS CQEVL RKGCL RFQLP ERGSR LCLYE DGTEL TEDYF PSVPD NAELV 
Hep3B MLQKP KSVKL RALRS PRKFG VAGRS CQEVL RKGCL RFQLP ERGSR LCLYE DGTEL TEDYF PSVPD NAELV 
Huh7  MLQKP KSVKL RALRS PRKFG VAGRS CQEVL RKGCL RFQNR KETHH HSYTGGSN 
J328  MLQKP KSVKL RALRS PRKFG VAGRS CQEVL RKGCL RFQNR KETHH HSYTGGSN 
Mahlavu   MLQKP KSVKL  RALRS PRKFG  VAGRS CQEVL  RKGCL  RFQLP  ERGSR  LCLYE  DATEL  TEDYF  PSVPD  NAELV
SK-Hep1   MLQKP KSVKL  RALRS SRKFG  VAGRS CQEVL  RKGCL  RFQLP  ERGSR  LCLYE  DGTEL  TEDYF  PSVPD  NAELV
 81    101  121 
Proto-type  LLTLQ QAWQG YVSDT RRFLS AFHEP QVGLI QAAQQ LLCDE QAPQR QRLLA DLLHN VSQNI AAETR AEDPP
HepG2 LLTLQ QAWQG YVSDT RRFLS AFHEP QVGLI QAAQQ LLCDE QAPQR QRLLA DLLLI KTLHQ PLQ 
Hep3B LLTLQ QAWQG CWSAV A
Huh7  
J328  
Mahlavu  LLTLQ QAWQG YNRKE THHHS YTGGS N
SK-Hep1  LLTLQ QAWQG CE
165 311  331 
Proto-type  WEEGL ESREQ ESREQ SKSGY LRYSC //  THKLN CDPSR IYKPO TRLKR KQPVR KRO
Figure 4 Scheme of the aberrant CAD transcripts and their predicted proteins. (A) The coding exons 1–7 are demonstrated as open squares. The heavy
lines in the transcripts in HepG2 cells represent a four-nucleotide identity at the two skipping ends (nucleotides 367–370 and 702–705, in accordance with
the numbering system by Mukae et al (1998)). The box labelled with ‘Alu’ in Hep3B cells represents a sequence homologous to a human Alu repeat. (B)
Alignment of the predicted amino-acid sequences for the aberrant CAD transcripts to the prototype CAD amino-acid sequences (Mukae et al, 1998). Note
that CAD domain (aa 1–80) is preserved in the aberrant transcripts from HepG2, Hep3B, Mahlavu and SK-Hep1 cells.
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level (Table 1).
The sub-full-length CAD transcript (representing three out of
the 10 isolated CAD cDNA clones) corresponding to replacement
of exon 3 with a truncated human transposon, Alu repeat, was
isolated in Hep3B cells. Alu elements are a specific human family
of interspersed repetitive sequences. It was estimated to be over
1000000 copies per genome. Their dispersion and plethora is
attributable to transposition via a mechanism that has not been
fully understood yet (Mathias et al, 1991). It was likely that the
CAD transcript with replacement of exon 3 with the Alu element
reported herein was generated via an Alu-mediated genomic
mutation mechanism. One possible mechanism is that a de novo
Alu-insertion mutation occurs in one of the two alleles of the CAD
gene. In theory, mobilization of Alu elements requires a cellular
source of reverse transcriptase that is generally believed to be
provided by a concurrently activated retrotransposon, such as
LINE-1 elements (Mathias et al, 1991). Indeed, global DNA
demethylation has been generally found in human cancers
including HCC (Lin et al, 2001), which in turn leads to activation
of transposable elements, such as LINE-1 and Alu repeats. It is,
therefore, conceivable to speculate that mutations secondary to
transposition of transposons in human cancers may not be rare
events. Indeed, de novo Alu insertion leading to human diseases,
particularly in tumours, has been reported before (Kazazian, 1998).
For examples, the insertions cause heamophilia B (factor IX gene)
(Vidaud et al, 1993), neurofibromatosis (NF-1 gene) (Walllace et al,
1991), Apert syndrome (FGFR2 gene), acholinesterasemia (ChE
gene) (Muratani et al, 1991), desmoid tumors (APC gene) and
breast cancer (Katagiri and Nakamura, 1996) (see the review by
Kazazian, 1998). Alternatively, this Alu-containing CAD transcript
might result from an Alu/Alu homologous recombination/deletion,
which led to exon 3 deletion and activation of a cryptic splicing
acceptor site in Alu elements. Experiments to elucidate the roles of
Alu-elements in genomic mutations for the CAD gene are in
progress.
On the other hand, the sub-full-length CAD transcripts found
in Huh7 and J328 cells exhibited loss of exons 2–6 and resulted
in fusion of exons 1 and 7. Since the fusion junctions just
coincided with the splice sites, they must be generated via
alternative splicing processes. Similar alternative spliced tran-
scripts with fusion of exons 1–7 were also found in the liver tissue
from a non-HCC subject and in the PBL from three healthy
individuals. The CAD reading frame encoded by these small
transcripts was so greatly disrupted that they might not have any
biological significance.
By contrast, the sub-full-length CAD transcripts found in poorly
differentiated HCC cells, Mahlavu and SK-Hep1, corresponded to
the absence of exons 3 to 6 or 5 and created a junction between
exon 2 to exon 7 or 6, respectively. Apparently, they were
generated via aberrant splicing mechanisms. These transcripts are
of great interest because not only were they cancer specific (only
found in poorly differentiated Mahlavu and SK-Hep1 cells) and
relatively abundant (30 and 70% of the isolated CAD cDNA clones,
respectively), but they also preserved the CAD domain (aa 1–80)
directing CAD interaction with its inhibitor (ICAD) (Mukae et al,
1998; Uegaki et al, 2000, Otomo et al, 2000). Since ICAD functions
as a chaperon for the regulation of CAD activity (Enari et al, 1998;
Sakahira et al, 1998; Sakahira et al, 2000), these predicted aberrant
CAD products might sequester ICAD from interacting with the
wild-type CAD, thereby preventing the correct folding of CAD and
subsequently blocking the nuclease activity of the wild-type CAD
in the cells. Interference of the CAD activity renders cells more
resistant to cell death, and in turn may award cells with advantages
for survival and, possibly, for carcinogenesis (Sakahira et al, 1998).
It is, therefore, intriguing to speculate that these aberrant CAD
products encoded by the aberrant CAD transcripts in SK-Hep1 and
Mahlavu cells (and those in HepG2 and Hep3B cells, Figure 4A and
B) play significant roles in cell apoptosis and in hepatocarcinogen-
esis. Indeed, in the experiments for DNA laddering under UV-
induced apoptosis, the phenomenon of DNA laddering was
remarkably impaired in Mahlavu and SK-Hep1 cells, and partially
impaired in HepG2 and Hep3B cells, as compared to that in HeLa,
Huh7 and J328 cells. Studies to further dissect the effects of these
C0- truncated CAD on nucleosome cleavage activities of the wild-
type CAD are currently ongoing.
Alternative splicing has been regarded as an important
mechanism that contributes to genetic diversity by generating
multiple protein isomers from a single gene (Croft et al, 2000;
Mironov et al, 2000). However, alternative splicing can also lead to
human disease (Blencowe, 2000; Philips and Cooper, 2000).
Alterations in alternative splicing of certain pre-mRNA have
recently been correlated to either neoplastic transformation and/or
acquisition of metastatic potential (Savagner et al, 1994; Cooper
and Dougherty, 1995; Barrack, 1996; Pfeffer, 1996; Skuse and
Cappione, 1997; Iwase et al, 1998; Philips and Cooper, 2000). Most
of these altered splicing patterns are because of either changes
in trans-acting factors or mutations within the canonical sequences
at the intro/exon border that are required for splicing. However,
mutations in an auxiliary element required for pre-mRNA
splicing within exons were found more recently. It was reported
that in human neuroblastomas, ataxia telangiectasia and breast
cancer some nonsense mutations caused skipping of exons, a
phenomenon known as nonsense-associated altered splicing
(Teraoka et al, 1999; Ars et al, 2000; Hastings and Krainer,
2001; Liu et al, 2001). The latter was attributable to result from
non-sense mutations in exon leading to disrupting a splicing
enhancer in exon, which contains recognition sequences for
splicing factors, such as SF2/ASF (Coulter et al, 1997; Hastings
and Krainer, 2001; Liu et al, 2001). The exon-skipping pheno-
type has been reproduced in vitro and was shown not to
result from disruption of the translational reading frame
(Blencowe, 2000). The canonical sequences at the intron-2/exon-
3 junction and the coding sequences in exon 3 for the CAD genes
in Hep3B, Mahlavu and SK-Hep1 cells have been examined.
However, neither mutations to disrupt the intro/exon sequence nor
non-sense mutations in exon 3 was found (data not shown).
Further studies to elucidate the underlying molecular mechanism
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Figure 5 ELISA for cellular DNA fragmentation. After 0, 100 or
200mJcm
 2 of UV irradiation, cytoplasmic lysate of cells containing DNA
metabolically prelabelled with BrdU was subjected to an ELISA with anti-
DNA antibody binding to fragmented DNA in cytoplasm followed by
quantification with a peroxidase-conjugated anti-BrdU antibody (Roche
Diagnostics GmbH, Mannheim, Germany). The representative results were
derived from experiments conducted in a manner of duplication for each
sample in every assay in a total of three assays. The averages and ranges of
the ratio of DNA fragmentation before vs after UV irradiation for each cell
line are illustrated. The relative amount of DNA fragmentation for each
HCC cell line was determined via comparison to that for HeLa cells.
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warranted.
In summary, we report the identity of aberrant transcripts and
frequent mutations for the CAD gene in human HCC cells,
suggesting a significant role of CAD in human hepatocarcino-
genesis.
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